Population pharmacokinetics of carbamazepine in adults with epilepsy

Nina M. Graves, Richard C. Brundage, Yandong Wen, Gregory D Cascino, Elson So, Peter Ahman, John Rarick, Sandra Krause, Ilo E. Leppik

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Study Objective. To conduct a population pharmacokinetic analysis of carbamazepine (CBZ). Design. Retrospective chart review. Setting. Ambulatory neurology clinics at three medical centers. Patients. Patients diagnosed with epilepsy from 1991-1995. The index set included 829 adults receiving CBZ. A separate validation set consisted of 50 patients. Interventions. None. Measurements and Main Results. Final regression equations were apparent oral clearance (CI/F) (L/hr) = (0.0134 · TBW + 3.58), · 1.42 if receiving phenytoin only; · 1.17 if receiving phenobarbital or felbamate; · 1.62 if receiving phenytoin and phenobarbital or felbamate; · 0.749 if age ≤ 70 years; apparent volume of distribution (V(d)/F) (L) = 1.97 · total body weight; absorption rate constant (hr-1) = 0.441. Interindividual variability in Cl/F and V(d)/F was 26% and 82%, respectively. Residual variability was 1.8 mg/L. Predictive performance analysis of the validation set provided a mean prediction error of 0.6 mg/L and median absolute error of 2.4 mg/L. Conclusions. These routinely collected data provided quantitative estimates of changes in CBZ Cl/F due to comedication and an age-related decrease in Cl/E. The derived regression equations reasonably predicted concentrations in a separate validation set.

Original languageEnglish (US)
Pages (from-to)273-281
Number of pages9
JournalPharmacotherapy
Volume18
Issue number2 I
StatePublished - Mar 1998

Fingerprint

felbamate
Carbamazepine
Epilepsy
Pharmacokinetics
Phenytoin
Phenobarbital
Population
Neurology
Body Weight

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Graves, N. M., Brundage, R. C., Wen, Y., Cascino, G. D., So, E., Ahman, P., ... Leppik, I. E. (1998). Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy, 18(2 I), 273-281.

Population pharmacokinetics of carbamazepine in adults with epilepsy. / Graves, Nina M.; Brundage, Richard C.; Wen, Yandong; Cascino, Gregory D; So, Elson; Ahman, Peter; Rarick, John; Krause, Sandra; Leppik, Ilo E.

In: Pharmacotherapy, Vol. 18, No. 2 I, 03.1998, p. 273-281.

Research output: Contribution to journalArticle

Graves, NM, Brundage, RC, Wen, Y, Cascino, GD, So, E, Ahman, P, Rarick, J, Krause, S & Leppik, IE 1998, 'Population pharmacokinetics of carbamazepine in adults with epilepsy', Pharmacotherapy, vol. 18, no. 2 I, pp. 273-281.
Graves NM, Brundage RC, Wen Y, Cascino GD, So E, Ahman P et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy. 1998 Mar;18(2 I):273-281.
Graves, Nina M. ; Brundage, Richard C. ; Wen, Yandong ; Cascino, Gregory D ; So, Elson ; Ahman, Peter ; Rarick, John ; Krause, Sandra ; Leppik, Ilo E. / Population pharmacokinetics of carbamazepine in adults with epilepsy. In: Pharmacotherapy. 1998 ; Vol. 18, No. 2 I. pp. 273-281.
@article{291978c75d8d4d4887429ab7c70ed2ec,
title = "Population pharmacokinetics of carbamazepine in adults with epilepsy",
abstract = "Study Objective. To conduct a population pharmacokinetic analysis of carbamazepine (CBZ). Design. Retrospective chart review. Setting. Ambulatory neurology clinics at three medical centers. Patients. Patients diagnosed with epilepsy from 1991-1995. The index set included 829 adults receiving CBZ. A separate validation set consisted of 50 patients. Interventions. None. Measurements and Main Results. Final regression equations were apparent oral clearance (CI/F) (L/hr) = (0.0134 · TBW + 3.58), · 1.42 if receiving phenytoin only; · 1.17 if receiving phenobarbital or felbamate; · 1.62 if receiving phenytoin and phenobarbital or felbamate; · 0.749 if age ≤ 70 years; apparent volume of distribution (V(d)/F) (L) = 1.97 · total body weight; absorption rate constant (hr-1) = 0.441. Interindividual variability in Cl/F and V(d)/F was 26{\%} and 82{\%}, respectively. Residual variability was 1.8 mg/L. Predictive performance analysis of the validation set provided a mean prediction error of 0.6 mg/L and median absolute error of 2.4 mg/L. Conclusions. These routinely collected data provided quantitative estimates of changes in CBZ Cl/F due to comedication and an age-related decrease in Cl/E. The derived regression equations reasonably predicted concentrations in a separate validation set.",
author = "Graves, {Nina M.} and Brundage, {Richard C.} and Yandong Wen and Cascino, {Gregory D} and Elson So and Peter Ahman and John Rarick and Sandra Krause and Leppik, {Ilo E.}",
year = "1998",
month = "3",
language = "English (US)",
volume = "18",
pages = "273--281",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2 I",

}

TY - JOUR

T1 - Population pharmacokinetics of carbamazepine in adults with epilepsy

AU - Graves, Nina M.

AU - Brundage, Richard C.

AU - Wen, Yandong

AU - Cascino, Gregory D

AU - So, Elson

AU - Ahman, Peter

AU - Rarick, John

AU - Krause, Sandra

AU - Leppik, Ilo E.

PY - 1998/3

Y1 - 1998/3

N2 - Study Objective. To conduct a population pharmacokinetic analysis of carbamazepine (CBZ). Design. Retrospective chart review. Setting. Ambulatory neurology clinics at three medical centers. Patients. Patients diagnosed with epilepsy from 1991-1995. The index set included 829 adults receiving CBZ. A separate validation set consisted of 50 patients. Interventions. None. Measurements and Main Results. Final regression equations were apparent oral clearance (CI/F) (L/hr) = (0.0134 · TBW + 3.58), · 1.42 if receiving phenytoin only; · 1.17 if receiving phenobarbital or felbamate; · 1.62 if receiving phenytoin and phenobarbital or felbamate; · 0.749 if age ≤ 70 years; apparent volume of distribution (V(d)/F) (L) = 1.97 · total body weight; absorption rate constant (hr-1) = 0.441. Interindividual variability in Cl/F and V(d)/F was 26% and 82%, respectively. Residual variability was 1.8 mg/L. Predictive performance analysis of the validation set provided a mean prediction error of 0.6 mg/L and median absolute error of 2.4 mg/L. Conclusions. These routinely collected data provided quantitative estimates of changes in CBZ Cl/F due to comedication and an age-related decrease in Cl/E. The derived regression equations reasonably predicted concentrations in a separate validation set.

AB - Study Objective. To conduct a population pharmacokinetic analysis of carbamazepine (CBZ). Design. Retrospective chart review. Setting. Ambulatory neurology clinics at three medical centers. Patients. Patients diagnosed with epilepsy from 1991-1995. The index set included 829 adults receiving CBZ. A separate validation set consisted of 50 patients. Interventions. None. Measurements and Main Results. Final regression equations were apparent oral clearance (CI/F) (L/hr) = (0.0134 · TBW + 3.58), · 1.42 if receiving phenytoin only; · 1.17 if receiving phenobarbital or felbamate; · 1.62 if receiving phenytoin and phenobarbital or felbamate; · 0.749 if age ≤ 70 years; apparent volume of distribution (V(d)/F) (L) = 1.97 · total body weight; absorption rate constant (hr-1) = 0.441. Interindividual variability in Cl/F and V(d)/F was 26% and 82%, respectively. Residual variability was 1.8 mg/L. Predictive performance analysis of the validation set provided a mean prediction error of 0.6 mg/L and median absolute error of 2.4 mg/L. Conclusions. These routinely collected data provided quantitative estimates of changes in CBZ Cl/F due to comedication and an age-related decrease in Cl/E. The derived regression equations reasonably predicted concentrations in a separate validation set.

UR - http://www.scopus.com/inward/record.url?scp=0031918974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031918974&partnerID=8YFLogxK

M3 - Article

C2 - 9545146

AN - SCOPUS:0031918974

VL - 18

SP - 273

EP - 281

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2 I

ER -